RARE insider transaction filings
Ultragenyx Pharmaceutical Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-04. Screen RARE transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-04 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 4,696 @ $24.92 | EDGAR |
| 2026-08-04 | 4 | Parschauer Karah Herdman — EVP and Chief Legal Officer | Sale (S): 1,900 @ $24.92 | EDGAR |
| 2026-07-06 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 4,698 @ $33.13 | EDGAR |
| 2026-06-15 | 4 | Sanders Corazon (Corsee) D. — Director | Sale (S): 2,000 @ $25.05 | EDGAR |
| 2026-06-15 | 4 | Parschauer Karah Herdman — EVP and Chief Legal Officer | Sale (S): 1,899 @ $24.62 | EDGAR |
| 2026-06-01 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 4,653 @ $23.77 | EDGAR |
| 2026-05-18 | 4 | Ray Amrit — Director | Grant/award (A): 7,751 @ $0 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Sanders Corazon (Corsee) D. — Director | Grant/award (A): 7,751 @ $0 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | SULIMAN SHEHNAAZ — Director | Grant/award (A): 7,751 @ $0 · Sale (S): 5,740 @ $25.12 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Fust Matthew K — Director | Grant/award (A): 7,751 @ $0 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | NARACHI MICHAEL — Director | Grant/award (A): 7,751 @ $0 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Dunsire Deborah — Director | Grant/award (A): 7,751 @ $0 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | WELCH DANIEL G — Director | Grant/award (A): 7,751 @ $0 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | Crombez Eric — EVP and Chief Medical Officer | Sale (S): 344 @ $24.96 | EDGAR |
| 2026-05-04 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 4,683 @ $24.90 | EDGAR |
| 2026-04-24 | 4 | Huizenga Theodore Alan — SVP, Chief Accounting Officer | Grant/award (A): 20,241 @ $0 · Grant/award (A): 7,348 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Huang Dennis Karl — See Remarks | Grant/award (A): 23,116 @ $0 · Grant/award (A): 79,936 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Pinion John Richard — See Remarks | Grant/award (A): 23,116 @ $0 · Grant/award (A): 79,936 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Parschauer Karah Herdman — EVP and Chief Legal Officer | Grant/award (A): 28,895 @ $0 · Grant/award (A): 49,960 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Harris Erik — EVP & Chief Commercial Officer | Grant/award (A): 28,895 @ $0 · Grant/award (A): 49,960 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Crombez Eric — EVP and Chief Medical Officer | Grant/award (A): 34,674 @ $0 · Grant/award (A): 59,952 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Horn Howard — Chief Financial Officer | Grant/award (A): 34,674 @ $0 · Grant/award (A): 59,952 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | KAKKIS EMIL D — President & CEO, Director | Grant/award (A): 76,745 @ $0 · Grant/award (A): 132,693 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 4,683 @ $20.97 | EDGAR |
| 2026-03-10 | 4 | Parschauer Karah Herdman — EVP and Chief Legal Officer | Sale (S): 6,018 @ $21.40 · Sale (S): 3,508 @ $22.67 | EDGAR |
| 2026-03-03 | 4 | Pinion John Richard — See Remarks | Grant/award (A): 11,137 @ $0 · Sale (S): 10,029 @ $22.80 | EDGAR |
| 2026-03-03 | 4 | Harris Erik — EVP & Chief Commercial Officer | Grant/award (A): 11,643 @ $0 · Sale (S): 10,539 @ $22.80 | EDGAR |
| 2026-03-03 | 4 | Parschauer Karah Herdman — EVP and Chief Legal Officer | Grant/award (A): 11,137 @ $0 · Sale (S): 8,135 @ $22.80 | EDGAR |
| 2026-03-03 | 4 | Huizenga Theodore Alan — SVP, Chief Accounting Officer | Tax withholding (F): 148 @ $23.39 · Sale (S): 1,632 @ $22.80 | EDGAR |
| 2026-03-03 | 4 | Horn Howard — Chief Financial Officer | Grant/award (A): 6,143 @ $0 · Sale (S): 5,290 @ $22.80 · Sale (S): 3,119 @ $22.54 · Sale (S): 1,635 @ $22.40 | EDGAR |
| 2026-03-03 | 4 | Crombez Eric — EVP and Chief Medical Officer | Grant/award (A): 11,643 @ $0 · Sale (S): 7,029 @ $22.80 | EDGAR |
| 2026-03-03 | 4 | Huang Dennis Karl — See Remarks | Grant/award (A): 11,137 @ $0 · Tax withholding (F): 999 @ $23.39 | EDGAR |
| 2026-03-03 | 4 | KAKKIS EMIL D — President & CEO, Director | Grant/award (A): 71,177 @ $0 · Sale (S): 54,404 @ $22.80 | EDGAR |
| 2026-02-03 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 3,061 @ $23.56 | EDGAR |
| 2026-01-05 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 3,150 @ $22.84 | EDGAR |
| 2025-12-30 | 4 | Huizenga Theodore Alan — SVP, Chief Accounting Officer | Sale (S): 85 @ $34.38 | EDGAR |
| 2025-12-11 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 3,081 @ $36.38 | EDGAR |
| 2025-10-14 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 7,942 @ $31.51 | EDGAR |
| 2025-09-19 | 4 | Huizenga Theodore Alan — SVP, Chief Accounting Officer | Sale (S): 64 @ $29.17 | EDGAR |
| 2025-09-12 | 4 | Parschauer Karah Herdman — EVP and Chief Legal Officer | Sale (S): 2,450 @ $31.17 | EDGAR |
| 2025-09-08 | 4 | Huizenga Theodore Alan — SVP, Chief Accounting Officer | Sale (S): 84 @ $31.39 | EDGAR |
| 2025-06-23 | 4 | Sanders Corazon (Corsee) D. — Director | Sale (S): 2,405 @ $37.39 | EDGAR |
| 2025-05-19 | 4 | SULIMAN SHEHNAAZ — Director | Grant/award (A): 5,740 @ $0 · Grant/award (A): 10,787 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Sanders Corazon (Corsee) D. — Director | Grant/award (A): 5,740 @ $0 · Grant/award (A): 10,787 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Ray Amrit — Director | Grant/award (A): 5,740 @ $0 · Grant/award (A): 10,787 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Fust Matthew K — Director | Grant/award (A): 5,740 @ $0 · Grant/award (A): 10,787 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | NARACHI MICHAEL — Director | Grant/award (A): 5,740 @ $0 · Grant/award (A): 10,787 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Dunsire Deborah — Director | Grant/award (A): 5,740 @ $0 · Grant/award (A): 10,787 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | WELCH DANIEL G — Director | Grant/award (A): 5,740 @ $0 · Grant/award (A): 10,787 (derivative) @ $0 | EDGAR |
| 2025-05-05 | 4 | Crombez Eric — EVP and Chief Medical Officer | Sale (S): 242 @ $35.11 · Sale (S): 520 @ $39.24 | EDGAR |
Recent 8-K events — Ultragenyx Pharmaceutical Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-19 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-11 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-03-30 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-03-12 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-02-23 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-02-12 | 8-K | 2.02 — Results of Operations and Financial Condition ? 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RARE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →